The first stop for professional medicines advice

Medicines planning

43 results

Applied filters

Understanding data exclusivity and market protection

11 July 2025Data exclusivity and market protection periods prevent generic or biosimilar competition for at least 10 years after the originator medicine is licensed.

Understanding patents

11 July 2025Patents allow the inventor a finite period of monopoly in exchange for publicising the idea. We explain how they work with respect to medicines.

Understanding generic and biosimilar market entry

11 July 2025New medicines have several protections against competition. Other factors influence availability of generics or biosimilars after loss of exclusivity.

Biosimilar and key generic medicines July 2025 update

9 July 2025An update supporting system implementation of biosimilar and key generic medicines. 9 July 2025.

Preparing to use aflibercept 2mg biosimilar

4 July 2025Aflibercept 2mg biosimilars for use in ophthalmology are expected in December 2025 for NHS use. We offer general information and implementation advice.

Preparing to use golimumab biosimilar

21 May 2025Golimumab biosimilars are expected soon. We offer general information and implementation advice.

National Homecare Medicines Committee regional contacts

12 May 2025Contact details of the homecare regional specialists within the UK who sit on the National Homecare Medicines Committee (NHMC).

Biosimilar and key generic medicines - April 2025 update

9 April 2025An update supporting implementation of biosimilar and key generic medicines for aflibercept, golimumab, nilotinib and ferric carboxymaltose.
Registration required

New Product Evaluations

14 November 2024A list of new product evaluations that are freely available to NHS staff.

Using our annual medicines planning publication, Prescribing Outlook

28 October 2024Users should be aware of the constraints and assumptions in creating Prescribing Outlook, as well as their responsibilities for use.